+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Premenstrual Syndrome Treatment Market by Treatment Type (Non Pharmacological Treatment, Pharmacological Treatment), End User (Home Care Settings, Hospitals, Specialty Clinics), Product Form - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 181 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5967666
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The premenstrual syndrome treatment market is advancing rapidly, reflecting significant innovation and diversification in how care is delivered to women globally. Senior decision-makers in healthcare, pharmaceuticals, and nutraceuticals face increasing complexity in navigating this dynamic environment, where evolving patient expectations and regulatory changes converge on multiple fronts.

Market Snapshot: Premenstrual Syndrome Treatment Market Growth Trajectory

The Premenstrual Syndrome Treatment Market grew from USD 1.79 billion in 2024 to USD 1.87 billion in 2025. It is expected to continue growing at a CAGR of 4.36%, reaching USD 2.32 billion by 2030. This sustained expansion is driven by the growing prevalence of premenstrual syndrome symptoms, the integration of digital therapeutics, and the ongoing refinement of both traditional and emerging therapies. Heightened awareness, improved access to care, and increased investment in novel solutions are accelerating market maturity and opportunity.

Scope & Segmentation

  • Treatment Types: Non-pharmacological treatments—such as cognitive behavioral therapy, lifestyle management, and nutritional supplements including amino acid derivatives, herbal extracts, and vitamins and minerals—alongside pharmacological approaches, including combined oral contraceptives, GABA analogs, and selective serotonin reuptake inhibitors.
  • End Users: Home care settings, hospitals, and specialty clinics provide a variety of treatment delivery environments accommodating diverse patient needs and driving product form preferences.
  • Product Forms: Options include capsules, oral liquids, and tablets, addressing varied patient preferences for dosing, ease of administration, and adherence.
  • Geographical Coverage: The Americas, Europe, Middle East & Africa, and Asia-Pacific feature unique regulatory and patient demand dynamics, from the United States and Brazil to China, India, and Australia.
  • Corporate Landscape: Major participants include Bayer AG, Pfizer Inc., Johnson & Johnson Services, Eli Lilly and Company, GlaxoSmithKline, Teva Pharmaceutical, Viatris, Novartis AG, Sanofi S.A., and Sun Pharmaceutical Industries.

Key Takeaways for Senior Decision-Makers

  • Increasing adoption of patient-centric, integrated care models leverages digital therapeutics and lifestyle management for holistic symptom relief and improved outcomes.
  • Strategic focus on both non-pharmacological and pharmacological modalities meets the rising demand for tailored, multi-modal interventions addressing both physiological and behavioral symptoms.
  • Advances in targeted nutraceuticals, including amino acid derivatives and botanical extracts, reflect a trend toward evidence-based supplementation to complement or substitute pharmaceutical options.
  • Regional regulation and local manufacturing trends support innovative supply chain models and region-specific product formulations, particularly in response to variable patient needs and preferences.
  • Collaborations across pharmaceutical, digital health, and academic sectors continue to shape product innovation and accelerate clinical validation, facilitating faster market response to emerging trends.
  • Data-driven development and digital integration enable real-time monitoring of treatment efficacy and patient engagement, informing ongoing product improvement and market positioning.

Tariff Impact on Supply Chains and Cost Structures

Impending United States tariff adjustments for 2025 will shift sourcing strategies and impact the pricing of both active pharmaceutical ingredients and nutritional supplement components. These changes are pushing manufacturers to diversify supplier networks, increase domestic investment, and adopt risk-sharing supply agreements. Regional expertise in ingredient sourcing and processing is anticipated to mitigate cost pressures and drive innovation aligned with local quality standards.

Methodology & Data Sources

This report employs an integrated methodology combining secondary research—such as peer-reviewed journals, regulatory datasets, and market publications—with primary qualitative interviews of clinicians, nutritionists, and supply chain experts. Patient surveys and data triangulation ensure that the findings reflect both clinical realities and market-informed perspectives.

Why This Report Matters

  • Enables stakeholders to develop and refine data-driven, patient-focused strategies that address evolving consumer and regulatory requirements in women’s health.
  • Facilitates better risk management and operational resilience by unpacking supply chain and tariff trends shaping the future of premenstrual syndrome therapeutic delivery.
  • Supports informed decision-making through detailed segmentation analysis, competitive mapping, and actionable recommendations tailored to diverse markets and end-user profiles.

Conclusion

Senior leaders are equipped with a robust roadmap to navigate the evolving premenstrual syndrome treatment landscape. This report provides clarity on market directions, practical insight into operational challenges, and guidance for achieving long-term growth and resilience.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rise of personalized genetic profiling for targeted premenstrual syndrome therapies
5.2. Integration of AI powered symptom prediction tools into premenstrual syndrome management apps
5.3. Expansion of telehealth based consultations for accessible premenstrual syndrome treatments
5.4. Growing adoption of CBD and cannabinoid formulations for alleviating PMS related symptoms
5.5. Integration of mindfulness based stress reduction programs in PMS treatment protocols
5.6. Innovations in microbiome targeted therapies for mitigating premenstrual symptom severity fluctuations
5.7. Increased investment in clinical trials for plant based adaptogens addressing PMS physical and emotional symptoms
5.8. Development of workplace policies offering flexible leave for managing premenstrual syndrome symptoms
5.9. Emergence of insurance coverage expansions for comprehensive menstrual health including PMS management therapies
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Premenstrual Syndrome Treatment Market, by Treatment Type
8.1. Introduction
8.2. Non Pharmacological Treatment
8.2.1. Cognitive Behavioral Therapy
8.2.2. Lifestyle Management
8.2.3. Nutritional Supplements
8.2.3.1. Amino Acid Derivatives
8.2.3.2. Herbal Extracts
8.2.3.3. Vitamins & Minerals
8.3. Pharmacological Treatment
8.3.1. Drug Class
8.3.1.1. Combined Oral Contraceptives
8.3.1.2. Gaba Analogs
8.3.1.3. Selective Serotonin Reuptake Inhibitors
9. Premenstrual Syndrome Treatment Market, by End User
9.1. Introduction
9.2. Home Care Settings
9.3. Hospitals
9.4. Specialty Clinics
10. Premenstrual Syndrome Treatment Market, by Product Form
10.1. Introduction
10.2. Capsule
10.3. Oral Liquid
10.4. Tablet
11. Americas Premenstrual Syndrome Treatment Market
11.1. Introduction
11.2. United States
11.3. Canada
11.4. Mexico
11.5. Brazil
11.6. Argentina
12. Europe, Middle East & Africa Premenstrual Syndrome Treatment Market
12.1. Introduction
12.2. United Kingdom
12.3. Germany
12.4. France
12.5. Russia
12.6. Italy
12.7. Spain
12.8. United Arab Emirates
12.9. Saudi Arabia
12.10. South Africa
12.11. Denmark
12.12. Netherlands
12.13. Qatar
12.14. Finland
12.15. Sweden
12.16. Nigeria
12.17. Egypt
12.18. Turkey
12.19. Israel
12.20. Norway
12.21. Poland
12.22. Switzerland
13. Asia-Pacific Premenstrual Syndrome Treatment Market
13.1. Introduction
13.2. China
13.3. India
13.4. Japan
13.5. Australia
13.6. South Korea
13.7. Indonesia
13.8. Thailand
13.9. Philippines
13.10. Malaysia
13.11. Singapore
13.12. Vietnam
13.13. Taiwan
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Analysis
14.3.1. Bayer AG
14.3.2. Pfizer Inc.
14.3.3. Johnson & Johnson Services, Inc.
14.3.4. Eli Lilly and Company
14.3.5. GlaxoSmithKline plc
14.3.6. Teva Pharmaceutical Industries Ltd.
14.3.7. Viatris Inc.
14.3.8. Novartis AG
14.3.9. Sanofi S.A.
14.3.10. Sun Pharmaceutical Industries Ltd.
15. ResearchAI
16. ResearchStatistics
17. ResearchContacts
18. ResearchArticles
19. Appendix
List of Figures
FIGURE 1. PREMENSTRUAL SYNDROME TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 12. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 14. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. PREMENSTRUAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 20. PREMENSTRUAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 21. PREMENSTRUAL SYNDROME TREATMENT MARKET: RESEARCHAI
FIGURE 22. PREMENSTRUAL SYNDROME TREATMENT MARKET: RESEARCHSTATISTICS
FIGURE 23. PREMENSTRUAL SYNDROME TREATMENT MARKET: RESEARCHCONTACTS
FIGURE 24. PREMENSTRUAL SYNDROME TREATMENT MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PREMENSTRUAL SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY LIFESTYLE MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY LIFESTYLE MANAGEMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY AMINO ACID DERIVATIVES, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY AMINO ACID DERIVATIVES, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY VITAMINS & MINERALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY VITAMINS & MINERALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY GABA ANALOGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY GABA ANALOGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL LIQUID, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL LIQUID, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 91. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 92. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 93. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 94. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 95. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
TABLE 96. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2030 (USD MILLION)
TABLE 97. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 98. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 99. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 100. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 101. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 102. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 103. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 104. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 105. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 106. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 107. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 108. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 109. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
TABLE 110. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2030 (USD MILLION)
TABLE 111. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 112. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 113. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 114. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 115. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 116. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 117. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 118. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 123. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
TABLE 124. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2030 (USD MILLION)
TABLE 125. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 126. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 127. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 128. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 133. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 134. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 135. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 136. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 137. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
TABLE 138. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2030 (USD MILLION)
TABLE 139. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 140. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 141. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 142. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 143. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 164. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 166. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
TABLE 168. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 170. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 172. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 176. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 177. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 178. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 179. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 180. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 181. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
TABLE 182. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2030 (USD MILLION)
TABLE 183. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 184. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 185. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 186. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 187. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 188. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 189. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 190. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 191. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 192. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 193. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 194. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 195. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
TABLE 196. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2030 (USD MILLION)
TABLE 197. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 198. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 199. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 200. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 201. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 202. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 203. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 204. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 205. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 206. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 207. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 208. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 209. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
TABLE 210. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2030 (USD MILLION)
TABLE 211. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 212. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 213. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 214. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 215. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 218. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 219. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 220. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 221. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 222. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 223. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
TABLE 224. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2030 (USD MILLION)
TABLE 225. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 226. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 227. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 228. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 229. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 232. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 233. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 234. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 235. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 236. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 237. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
TABLE 238. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2030 (USD MILLION)
TABLE 239. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 240. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 241. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 242. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 243. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 244. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 245. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 246. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 262. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 264. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
TABLE 266. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 268. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 270. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 272. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 274. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 276. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 278. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
TABLE 280. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 282. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 284. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 286. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 287. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 288. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 289. DENMARK PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 290. DENMARK PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE,

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Premenstrual Syndrome Treatment market report include:
  • Bayer AG
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Novartis AG
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.

Table Information